Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients.
about
Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection.Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipientsDiagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patientsPhysical and chemical methods for enhancing rapid detection of viruses and other agents.Overview of the diagnosis of cytomegalovirus infection.Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients.Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS.Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytesRapid diagnosis of cytomegalovirus encephalitis in patients with AIDS using in situ hybridisation.Direct quantification of human cytomegalovirus immediate-early and late mRNA levels in blood of lung transplant recipients by competitive nucleic acid sequence-based amplification.Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification.Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.Endothelial cells and CMV dissemination.Comparison of several fixation methods for cytomegalovirus antigenemia assay.Comparison of nested PCR for detection of DNA in plasma with pp65 leukocytic antigenemia procedure for diagnosis of human cytomegalovirus infection.Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis.Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia.Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay.Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins.Prospective study of cytomegalovirus antigenemia in allograft recipients.Cytomegalovirus antigenemia assay.Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement.Chemiluminescent in situ hybridization for the detection of cytomegalovirus DNA.Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients.
P2860
Q33662067-7E1808AD-1612-4B69-90C4-CE50323D1BF4Q33966910-A245C061-D4E3-4160-B82D-8EF0667038B8Q34102747-6E87598C-B34A-4372-8B60-EC97C2D1027FQ34257412-118C5D1D-7079-492D-A595-EF1DF66F7DE7Q35227779-633347AD-0EAE-4C6F-82ED-76AFC28FC3B1Q36639842-0699E1F4-EBDE-4D18-8121-92ED1F0F4D8FQ37062282-0B4BCFB9-AD36-437C-BC6C-221B71AC5F4AQ37116756-1775A3B7-ED8E-4E5E-9257-8FD617DA4E61Q37139100-2BA0DBD5-A5BF-4174-95FD-B13D74301203Q37249381-9A1FB255-8337-44B6-A8B4-DFB5295B1E1DQ37253550-60993EF3-854F-4D31-B1DE-B1599326F753Q39462962-BF3A2CCC-792B-48D6-9CA0-445A0B4A2953Q39467685-B47D3284-5784-4008-B999-AF5741CB2847Q39591457-6F4478A1-D1C9-4ACA-B906-82A96FCCDC79Q39637767-817E391C-FF0C-4549-BE4B-80870DA33EE4Q40007973-63AD23FB-0A4B-452A-BF69-DBCBAF848063Q40180430-C577BA57-4D7B-453E-B9E5-EB102C3EBBD1Q40180848-5DEB0B41-61EB-44BD-967B-63335B187C3EQ40186252-A0156963-95F9-41E2-BB61-AD201810AD98Q40198082-B574896B-15FE-47A0-B8DA-197308D5D96DQ40203314-221548D1-551B-476C-8EAB-D72C23F61A81Q40211986-37BE0ECE-4A41-4EEA-AC6D-0A97A22BAAADQ40214631-62B317E5-0045-4783-AAD3-69C9766C12BAQ40339181-265E1BEC-9D5D-4237-909B-C96C6F1E3E5CQ41210063-7AB9B87F-D43D-435F-875A-B20455F1A258Q43778417-CABEABF1-4A7B-4F3E-A74A-1CAD1B496059Q44821348-0A2F22B7-BD68-4F74-BF36-70924C119584
P2860
Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Detection of human cytomegalov ...... in immunocompromised patients.
@en
type
label
Detection of human cytomegalov ...... in immunocompromised patients.
@en
prefLabel
Detection of human cytomegalov ...... in immunocompromised patients.
@en
P2093
P356
P1476
Detection of human cytomegalov ...... in immunocompromised patients.
@en
P2093
P356
10.1002/JMV.1890290204
P577
1989-10-01T00:00:00Z